指南与共识胸部肿瘤

紫杉醇治疗药物监测——国际治疗药物监测与临床毒理学协会推荐

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
指南 / 共识 · Eur J Cancer · 2024-03-19

紫杉醇按体表面积给药导致全身暴露个体差异大。该国际协会基于临床证据评估紫杉醇治疗药物监测(TDM)的科学依据与临床获益,强烈推荐晚期非小细胞肺癌每3周紫杉醇联合铂类治疗时行TDM,对其他瘤种3小时输注推荐强度为中等证据,1小时输注仅有初步证据提示可能有用。

要点

  • 晚期非小细胞肺癌每3周紫杉醇联合铂类治疗:强烈推荐行TDM。
  • 其他肿瘤类型紫杉醇3小时输注:中等证据推荐行TDM。
  • 紫杉醇1小时输注:初步证据提示TDM可能有用。

核心结论

  • 基于综述证据,强烈推荐晚期非小细胞肺癌患者接受每3周紫杉醇联合铂类治疗时行TDM,因前瞻性研究已证实临床获益。
  • 对其他肿瘤类型的紫杉醇3小时输注,有中等证据推荐行TDM。
  • 对紫杉醇1小时输注,初步证据提示TDM可能有用。
  • 尽管TDM获益已获证实,因样本采集与分析存在挑战,临床采用仍有限。

研究设计与样本

  • 国际治疗药物监测与临床毒理学协会基于对紫杉醇个体化给药相关临床证据的综述提出推荐。

主要发现

  • 回顾性研究显示,在多种疾病类型和给药方案中,紫杉醇全身暴露较高与毒性和疗效增加相关。
  • 前瞻性试验显示,TDM可降低全身暴露的变异性,并已在晚期非小细胞肺癌每3周给药方案中证实可降低毒性且保留疗效。

关键数值与推荐

  • 晚期非小细胞肺癌每3周紫杉醇联合铂类:强烈推荐TDM。
  • 其他肿瘤类型紫杉醇3小时输注:中等证据推荐TDM。
  • 紫杉醇1小时输注:初步证据提示TDM可能有用。

临床怎么用

  • 原文未据此给出TDM具体操作推荐。

局限性

  • 尽管TDM获益已获证实,因样本采集与分析存在挑战,临床采用仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens. In prospective trials, TDM reduces variability in systemic exposure, and has been demonstrated to reduce toxicity while retaining treatment efficacy for 3-weekly dosing in patients with advanced non-small cell lung cancer. Despite the demonstrated benefits of paclitaxel TDM, clinical adoption has been limited due to the challenges with sample collection and analysis. Based on our review, we strongly recommend TDM for patients receiving every 3-week paclitaxel in combination with a platinum agent for advanced NSCLC, due to the prospectively demonstrated clinical benefits, and find moderate evidence to recommend TDM for paclitaxel 3-hour infusions for other tumor types and preliminary evidence suggesting potential usefulness for paclitaxel administered by 1-hour infusions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hertz DL, Joerger M, Bang YJ, et al. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024. PMID: 38513383. doi:10.1016/j.ejca.2024.114024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。